Protein buildup in brain vessels quadruples dementia risk, study finds

A condition most people have never heard of is quietly linked to a sharp rise in dementia risk. Cerebral amyloid angiopathy — CAA for short — happens when a protein called amyloid accumulates in the brain's blood vessels, gradually weakening them. A large new study of nearly 2 million older Americans found that people with CAA were about four times more likely to develop dementia within five years, whether or not they'd ever had a stroke.

The finding matters because it rewrites how doctors should think about dementia risk. For years, stroke was seen as the main pathway from CAA to cognitive decline. But this research suggests the protein buildup itself — independent of whether it causes a stroke — is doing most of the damage.

What the data showed

Researchers analyzed Medicare records from 1.9 million adults age 65 and older between 2016 and 2022, tracking new dementia diagnoses and how both stroke and CAA affected risk. The numbers were stark: 42% of people with CAA received a dementia diagnosis within five years, compared to just 10% of those without CAA. People with CAA but no stroke history were 4.3 times more likely to develop dementia than those with neither condition. Those with both CAA and stroke faced 4.5 times the risk.

What stood out to researchers was how similar the dementia risk was between CAA patients with and without stroke. "This suggests that non-stroke-related mechanisms are instrumental to dementia risk in CAA," said study author Samuel S. Bruce, an assistant professor of neurology at Weill Cornell Medicine. In other words, the amyloid itself — not just the bleeding or clotting it can cause — appears to be driving cognitive decline.

The finding opens a practical door. If doctors know CAA patients face such high dementia risk regardless of stroke, they should be screening these patients early and aggressively for memory and thinking problems. Catching cognitive changes sooner could mean starting interventions before decline accelerates.

The broader picture

CAA often coexists with Alzheimer's disease, creating what researchers call a "potent 1-2 punch." Small vessel disease — of which CAA is a major type — is now recognized as a leading contributor to dementia, sometimes working alongside other brain changes to compound risk. The condition is more common than most people realize, though still relatively rare in the general population. Among the nearly 2 million Medicare patients in this study, only 752 (0.04%) had a CAA diagnosis on record, but that likely reflects both the condition's actual rarity and significant underdiagnosis.

The study does have limitations worth noting. The research relied on insurance billing codes rather than detailed clinical imaging, which means some diagnoses may have been misclassified. The researchers called for future studies that follow patients forward in time with standardized diagnostic methods to confirm these findings.

Still, the message is clear: CAA deserves far more clinical attention than it currently receives. For the millions of older adults living with this condition, early cognitive screening and proactive management of risk factors could slow the path to dementia.